February 2026—Revvity launched highly characterized somatic cancer reference standards developed in collaboration with the Medical Device Innovation Consortium and National Institute of Standards and Technology as part of the Somatic Reference Samples Initiative.
The Mimix Geni reference standards were developed from the Genome in a Bottle Consortium cell line and engineered by Revvity to contain seven oncogenic mutations. Each mutation was selected for its clinical significance by industry experts, including representatives from NIST, the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. The standards have undergone extensive testing and validation by MDIC and NIST, with further validation by multiple labs planned soon.
Revvity, 800-762-4000